Enliven Therapeutics, Inc (ELVN) Tops Q3 EPS by 3c

Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q3 EPS of ($0.48), $0.03 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• BXP Inc. (BXP) PT Raised to $70 at UBS as Earnings Outlook Accelerates
• Rush Enterprises Inc. (RUSHA) PT Raised to $85 at UBS